生物技术公司Corvus Pharmaceuticals, Inc.（股票代码：CRVS）今日盘中股价大跌5.18%，引起了市场的关注。
消息面上，该公司宣布与投资银行杰富瑞（Jefferies）扩大了场内股票销售协议，将金额上限从原先的1亿美元提高至2亿美元，翻了一倍。新协议允许Corvus通过多种方式出售股票，包括私人交易和大宗交易。根据文件，杰富瑞将从出售的任何股票中获得最多3%的佣金，而Corvus尚未根据先前的协议出售任何股票。
市场分析认为，扩大股票销售协议可能意味着公司计划进行更大规模的股权融资，这通常会稀释现有股东的权益，因此被视作利空消息。此外，该股今年以来已上涨约两倍，部分投资者可能选择在此消息后获利了结，加剧了股价的下跌压力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.